Regulus Therapeutics prices IPO at $4.00 as expected

By
A A A

Regulus Therapeutics, an early stage biotech developing microRNAs treatments for multiple serious diseases, raised $45 million by offering 11.3 million shares at $4 per share. The company, which was previously expecting to raise $50 million by offering 4.5 million shares at a range of $10 to $12, revised its terms this morning in an amendment filed with the SEC. Regulus Therapeutics listed on the NASDAQ under the symbol RGLS and is trading up about 14% today. Lazard Capital Markets, Cowen & Company and BMO Capital Markets acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RGLS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

32,095,259
  • $42.865 ▲ 1.85%
23,630,651
  • $47.06 ▲ 0.81%
22,001,317
  • $17.065 ▲ 0.15%
21,154,201
  • $5.15 ▼ 4.81%
18,977,902
  • $101.69 ▼ 0.10%
16,473,168
  • $34.975 ▼ 0.55%
16,313,178
  • $39.66 ▼ 4.55%
13,957,531
  • $25.255 ▲ 0.14%
As of 9/19/2014, 10:07 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com